Drug news

ROVA-T failed MERU trial for small cell lung cancer and theprogramme has been terminated

Read time: 1 mins

Last updated:30th Aug 2019

Published:30th Aug 2019

Source: Pharmawand

AbbVie, announced that MERU, a Phase III trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with placebo.

The overall safety profile was generally consistent with that observed in previous studies. The MERU trial is being closed, and the Rova-T research and development program has been terminated. AbbVie will move forward prioritizing other development programs within its oncology pipeline.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, interchangeable biosimilar to Humira

Boehringer Ingelheim announced that the FDA has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases

1 mins

Drug news

FDA approval for Inceptiv closed-loop spinal cord stimulator stimulator (SCS)for the treatment of chronic pain

Medtronic plc announced that the FDA has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain

1 min

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 min

See all news